Data / Form D filings / Precise Bio, Inc.
Precise Bio, Inc.: Form D filings
Precise Bio, Inc., a biotechnology company in Winston-Salem, NC, filed 2 Form D notices with the SEC between 2022 and 2024. The latest, on January 17, 2024, reports $12 million sold of a $25 million offering to 8 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 111 NORTH CHESTNUT STREET, SUITE 103, Winston-Salem, NC, 27101
- Phone
- (336) 955-1120
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1904090
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | New notice | $25,000,000 | $12,000,000 | $13,000,000 | 8 | Jul 14, 2022 | sec.gov |
| Feb 9, 2022 | New notice | $15,530,000 | $15,530,000 | 70 | Nov 3, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Nathan Cali | Director | |
| Viko Dana | Director | |
| Aryeh Batt | Executive Officer, Director, Promoter | |
| Shay Soker | Director, Promoter | |
| Dirk Muehlhoff | Director | |
| Ilan Lior | Director | |
| Ori Hadimi | Executive Officer, Director | |
| Avi Katz | Director | |
| Anthony Atala | Director, Promoter |
Other biotechnology companies in North Carolina that filed recently
- Toggle Bio $200,000 · Oct 6, 2026
- Swift Cardiovascular, Inc. $810,000 · Sep 24, 2026
- Aclarity Genomics, Inc. $4.6 million · Sep 2, 2026
- Aer Therapeutics, Inc. $3 million · Aug 19, 2026
Every Form D from the week of Jan 15, 2024 · All recent filings in North Carolina · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Precise Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.